Top Markets
#1 EXOD EXOD +56.80%
#2 Glidr Glidr +33.64%
#3 Cysic Cysic +25.00%
#4 Nockchain Nockchain +18.92%
#5 Velvet Velvet +18.00%
#6 Perle Perle +14.46%
#7 FOLKS FOLKS +13.61%
#8 Nillion Nillion +12.50%
#9 Versatize Coin Versatize Coin +12.49%
#10 Starpower Starpower +10.78%
Coin of the day
EXOD EXOD
Settings
Language
ENGLISH
Currency
USD
Theme
Sirona Biochem Corp. Sirona Biochem Corp.

Sirona Biochem Corp.

SRBCF
Rank in Stocks #37537
Sirona Biochem Corp. operates as a biotechnology company dedicated to... Sirona Biochem Corp. operates as a biotechnology company dedicated to uncovering and commercializing active ingredients for both cosmetic and pharmaceutical uses, with a commercial presence in Canada and France. Key initiatives include the development of a cosmetic skin brightener and a pharmaceutical solution for diabetes. Beyond these, the company is engaged in several other projects, such as building a library of anti-aging and cell-protective compounds, creating a novel anti-wrinkle agent, and pursuing an antiviral research program. A notable collaboration exists with the International Centre for Genetic Engineering and Biotechnology (ICGEB) for the joint development of an antiviral compound library. Established in 2006, the business, originally named High Rider Capital Inc., rebranded as Sirona Biochem Corp. in May 2009 and maintains its headquarters in Vancouver, Canada.
Share Price
$0.0051
Last synced: 2026-08-13
Market Cap
$1.63M
Change (1 day)
0.00%
Change (1 year)
-60.31%
Country
CA
Trade Sirona Biochem Corp. (SRBCF)

Category

Healthcare
Revenue for Sirona Biochem Corp. (SRBCF)
Revenue in Aug 2026 TTM: 0
According to Sirona Biochem Corp. latest financial reports the company's current revenue (TTM) is 0. In 2026 the company made a revenue of 0 equal to the revenue in the year 2026 that was 0. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history for Sirona Biochem Corp. from 2026 to 2026
Revenue at the end of each year
Year Revenue Change
Not enough data for the provided dates.
Revenue for similar companies or competitors
Company Revenue Revenue Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B -
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
 - -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
 $10.11B -
BE